Vaping and Harm Reduction

Strip the politics and a factual spine remains: e-cigarette aerosol contains far lower levels of the combustion toxicants that kill smokers — no tar, no carbon monoxide, sharply reduced carcinogens in biomarker studies — making vaping substantially less harmful than smoking while not harmless, with long-term (multi-decade) effects genuinely unknown; nicotine itself is addictive but is not the primary carcinogen in tobacco; randomised trials, synthesised by Cochrane with high-certainty evidence, show e-cigarettes outperform nicotine-replacement therapy for smoking cessation; and youth uptake of vaping surged in the late 2010s in country after country, creating a nicotine-dependence problem in people who would mostly never have smoked. Every honest national policy is an attempt to keep the first set of facts working for smokers while containing the last one — and countries have made radically different bets.

The UK built policy on the harm-reduction reading: health agencies endorse vaping for adult smokers trying to quit (the famous, contested framing of around 95% less harmful originated in English public health reviews), the NHS incorporates vapes into cessation support including a national swap-to-stop scheme, and the results table is at least consistent with the bet: adult smoking has fallen to historic lows, with 18-24-year-old smoking collapsing from around 26% in 2011 to 8% by 2024 while vaping rose then stabilised — a pattern suggesting diversion from cigarettes outweighing any gateway effect at population level. The corrective wave then targeted youth specifically: disposables banned from June 2025, all-vape age restriction at 18, advertising and packaging limits in the Tobacco and Vapes Bill, and a vape-liquid duty from October 2026 — regulation aimed at the products teenagers used, while keeping the quitting tool available to smokers.

Britain's disposables ban is now the best-documented vaping intervention anywhere, and its first-year results are instructively mixed. What moved: disposable use collapsed — among 11-17-year-old vapers, mainly-disposable use fell from 42% before the ban to 13% a year after; among adult vapers from roughly a quarter to under a tenth, with time-series analysis putting disposable use at a fraction of its no-ban counterfactual. What the ban did not clearly do: reduce overall vaping prevalence, which plateaued rather than fell as users shifted to reusable and refillable devices — many functionally similar to the banned products; and smoking declines briefly slowed (and in young adults temporarily reversed) around the announcement before resuming after implementation, a nervous moment for the harm-reduction ledger. What it produced as side effect: a documented illicit market — over 1.3 million illegal vape products seized by councils in 2025, and tenfold rises in illegal-sales reports in Wales. The verdict so far: bans move products, markets adapt, and the prevalence and smoking effects that actually matter need longer follow-up.

The US wrote the cautionary chapters. The 2019 EVALI outbreak — thousands hospitalised, dozens dead — was traced overwhelmingly to vitamin E acetate in illicit THC cartridges, not nicotine vaping, yet remains cited as a vaping harm in ways that measurably shifted smokers' risk perceptions toward wrongly believing vaping equals or exceeds smoking's dangers — a misinformation legacy with its own body count if it deters switching. Youth vaping peaked in 2019 with over a quarter of high-schoolers currently vaping amid the Juul era, then fell steeply through the 2020s under flavour restrictions, enforcement and cohort change — down to single digits — demonstrating that youth waves can recede without abandoning adult harm reduction. The US regulatory legacy is otherwise chaotic: a slow authorisation pathway that approved few products while an unregulated (often illegally imported) disposable market flourished — the worst of both worlds, restricting the compliant while the non-compliant sold freely.

Policy has trifurcated: harm-reduction integration (UK, New Zealand — whose smoked-tobacco denicotinisation and generational-ban experiments were partly reversed by politics), prescription-only or effective prohibition (Australia's pharmacy model, India's ban, Brazil), and the WHO's precautionary line urging strict regulation, which harm-reduction advocates accuse of conflating vaping with smoking. Underneath sit the genuine open questions all camps should admit: multi-decade respiratory and cardiovascular effects are unknowable yet (the products are too young); dual use — vaping while still smoking — captures little benefit and describes many real-world users; youth nicotine dependence has its own costs even if those users never smoke; flavour policy embodies a real trade-off (flavours recruit teenagers and help adult switchers — both findings are solid); and the counterfactual question defining everything — how many vapers would otherwise smoke — resists clean measurement. Certainty on offer from either side of this debate is a sales pitch.

For smokers: switching completely to vaping is one of the best-evidenced quitting routes available — better than patches and gum in trials — and the operative word is completely: dual use forfeits most of the benefit; regulated products from legitimate retailers only, and treat quitting vaping later as a real second step worth planning. For never-smokers, especially young people: there is no health case for starting — vaping is a harm-reduction tool, which requires a harm to reduce; nicotine dependence is easy to acquire and tedious to shed. For parents: disposable-era ubiquity is receding under regulation, but access endures through illicit channels — the useful conversations mirror the alcohol ones: dependence, sleep, money, and marketing literacy. For policymakers: the British and American records together suggest the workable frame — adult access with quality control, youth-targeted product and marketing restrictions, honest relative-risk communication, and enforcement resourced as seriously as legislation.